Precipio Reports Q3 2026 Revenue Growth Driven by Product Segment Expansion
Precipio, Inc. (PRPO) reported third-quarter 2026 results showing a total revenue of $7.3 million, an 8% increase year-over-year. A significant highlight was the product revenue segment, which reached $1.0 million—a 40% year-over-year increase and the first time this segment exceeded the $1 million threshold in a single quarter. The company is transitioning from a phase of achieving financial independence toward an aggressive growth strategy aimed at reaching a combined annualized revenue run rate of $40 million by the end of 2027. To support this, management plans to double its commercial team size and leverage major distribution partnerships with Thermo Fisher, Medline, McKesson, and Cardinal Health. While pathology services remain the primary driver of operating cash flow, the company is focused on scaling product margins from current levels of 40-50% toward a target of 70-75%. Management noted that while infrastructure can support up to $100 million in revenue without significant new capital, variable customer onboarding timelines (3 to 18 months) remain a forecasting challenge.
Topics: Adjusted EBITDA Cash Flow Financial Guidance Pathology Revenue Product Revenue Revenue Growth